Journal of Medical Virology · 2003 · 17 citations · 33 references
Life SciencesGeneticsMolecular GeneticsHepatologyMolecular VirologyVirologyAntiviral TherapyInterferon-based TherapyViral EvolutionViral GeneticsViral HepatitisViral MutationAntiviral TreatmentGenetic Heterogeneity AnalysisHepatitis B E AntigenHepatitis B Surface Antigen LossHepatitis B Virus GenotypeHepatitis C Virus GenotypeLamivudine TherapySeroconversion Rates
It has been reported that spontaneous or interferon (IFN)-induced hepatitis B e (HBe) seroconversion has usually been associated with the development of a stop codon in the precore region. However, the difference between lamivudine-induced seroconversion and spontaneous or IFN-induced seroconversion is not known. The aim of this study was to investigate the correlation between the evolution of the precore and core promoter mutations and lamivudine-induced seroconversion. Forty-five patients with chronic hepatitis B virus (HBV) infection who were treated with lamivudine for more than 1 year were enrolled. The nucleotide sequence of the precore and core promoter region was determined before and after treatment with lamivudine for 1 year. Among 29 patients who were hepatitis B e antigen (HBeAg)-positive before treatment, 12 (41.3%) lost HBeAg during the course of treatment for 1 year. Of these, eight patients (66.7%) still had precore wild type HBV after 1 year. After 1 year, reversion to precore wild type HBV was detected in 11 (64.7%) of 17 patients who had precore mutant HBV before treatment. Twelve (70.6%) of 17 patients who were persistently HBeAg-positive had precore wild type HBV before and after treatment for 1 year. Despite the loss of HBeAg, two thirds of the patients still had precore wild type HBV after the 1-year treatment. It is suggested that lamivudine-induced seroconversion differs from spontaneous or IFN-induced seroconversion in the change of nucleotides in the precore region. The reversion in the precore region may be caused by the difference of drug-susceptibility to lamivudine. The antiviral effect of lamivudine may be more effective in the precore mutant HBV than in the precore wild type HBV.
33
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Ching‐Lung Lai, Rong‐Nan Chien, Nancy W.Y. Leung et al. · New England Journal of Medicine · 1998 · 1.8K citations · Full text
LAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
J Ules, L. D Ienstag, E Ugene R. S Chiff et al. · 1999 · 1.1K citations
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
Jia‐Horng Kao, Pei‐Jer Chen, Ming–Yang Lai et al. · Gastroenterology · 2000 · 940 citations · Full text